{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:44:39Z","timestamp":1778946279061,"version":"3.51.4"},"reference-count":8,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2024,3,30]]},"DOI":"10.1536\/ihj.23-355","type":"journal-article","created":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T22:18:01Z","timestamp":1711750681000},"page":"349-353","source":"Crossref","is-referenced-by-count":3,"title":["Ponatinib-Related Vasospastic Angina"],"prefix":"10.1536","volume":"65","author":[{"given":"Michiho","family":"Shindo","sequence":"first","affiliation":[{"name":"Department of Cardiology, Toranomon Hospital"},{"name":"Department of Hematology, Toranomon Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chinatsu","family":"Komiyama","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Toranomon Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuo","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Toranomon Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosei","family":"Kageyama","sequence":"additional","affiliation":[{"name":"Department of Hematology, Toranomon Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Hematology, Toranomon Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yo","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Toranomon Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoyuki","family":"Uchida","sequence":"additional","affiliation":[{"name":"Department of Hematology, Toranomon Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahide","family":"Kodama","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Toranomon Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Braun TP, Eide CA, Druker BJ. Response and Resistance to BCR-ABL1-Targeted Therapies. Cancer Cell 2020; 37: 530-42.","DOI":"10.1016\/j.ccell.2020.03.006"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Cortes JE, Kim D, Pinilla-Ibarz J, <i>et al<\/i>. ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood 2018; 132: 393-404.","DOI":"10.1182\/blood-2016-09-739086"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Jain J, Kantarjian H, Boddu PC, <i>et al<\/i>. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. Blood 2019; 3: 851-61.","DOI":"10.1182\/bloodadvances.2018025874"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Valent P, Hadzijusufovic E, Hoermann G, <i>et al<\/i>. Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML. Leuk Res 2017; 59: 47-54.","DOI":"10.1016\/j.leukres.2017.05.008"},{"key":"5","unstructured":"5. Fiets RB, Staal AHJ, Blijlevens NMA. Coronary artery spasms due to tyrosine kinase inhibitors used in chronic myeloid leukemia. Neth J Med 2018; 76: 330-5."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Scalone G, Mariani L, Aimi A, Grossi P, <i>et al<\/i>. Coronary epicardic vasospasm in patient treated with desatinib for lymphoblastic leukaemia: the other side of the medal. Eur Heart J 2019; 40: 1235.","DOI":"10.1093\/eurheartj\/ehz054"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Latifi Y, Moccetti F, Wu M, <i>et al<\/i>. Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib. Blood 2019; 133: 1597-606.","DOI":"10.1182\/blood-2018-10-881557"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Boddu P, Shah AR, Borthakur G, <i>et al<\/i>. Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting. Leuk Lymphoma 2018; 59: 1312-22.","DOI":"10.1080\/10428194.2017.1379076"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/65\/2\/65_23-355\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T04:44:51Z","timestamp":1711773891000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/65\/2\/65_23-355\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,30]]},"references-count":8,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.23-355","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,30]]},"article-number":"23-355"}}